Merck & Co.Inc., and Samsung Bioepis have jointly terminated development of Lusdarna a diabetes insulin treatment biosimilar.
Merck & Co.Inc., and Samsung Bioepis have jointly terminated development of Lusdarna a diabetes insulin treatment biosimilar that used Sanofi's Lantus as a reference drug.
According to a Korean stock exchange disclosure form, Merck will pay Samsung Bioepis a termination fee of roughly $155 million. The disclosure also stated that Samsung Bioepis had invested a total of about $91 million in the drug, leaving a net profit from the cancellation of roughly $64 million.
Lusdarna was cancelled by the companies after a recent review of the market for the drug, including looking at pricing and cost production expectations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.